Search

Abstract: Although there have been numerous advancements in burn wound management, burn injuries are still a major cause of morbidity and mortality in the United States, and novel therapeutics are still needed to improve outcomes. Poloxamer 188 (P188) is a synthetic copolymer with Food and Drug Administration (FDA) approval that has many biological applications. This study aimed to review the literature on P188 in burn injuries and its effects based on burn mechanisms. We employed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to complete this systematic literature review. We searched the databases of Google Scholar, PubMed, and SCOPUS using the keywords burn, p188, poloxamer 188, and pluronic F68 in combination. Two reviewers independently screened the articles for inclusion. Articles that were not in English, were book chapters or conference proceedings, or did not evaluate P188 in the setting of burn injuries were excluded. We included a total of 33 full-text articles with both in vivo and in vitro preclinical studies. P188 was found to be beneficial in animal and cell studies evaluating electrical and thermal burn injuries. P188 was also found to be useful in burn wound management. Although its utility may be limited in radiation injuries, P188 may be helpful in delaying the initial damage caused by radiation burns. P188 therefore has the potential to be used as a therapy in both burn wound management and in the treatment of systemic injuries sustained through burns. Future studies should aim to assess the efficacy of P188 in clinical models of burn injury., Competing Interests: The authors report no conflicts of interest., (Copyright © 2024 by the Shock Society.)

Traumatic Brain Injury (TBI) is a major cause of severe disability and death, resulting in significant health care and economic burden. Poloxamer 188, a synthetic tri-block copolymer approved by the FDA, has been studied for its potential effects on traumatic brain injury (TBI). The neuroprotective abilities of P188 have attracted significant attention. This systematic review aims to compile evidence of P188's effect on the treatment of TBI. A comprehensive literature search was conducted using PubMed, SCOPUS, and Google Scholar databases, which yielded 20 articles that satisfied the inclusion criteria. These articles have shown direct protective effects of P188 on brain tissue following TBI, including restitution of the increase cell membrane permeability, attenuation of neuronal necrosis and apoptosis, improvement of mitochondrial viability, reduction in axonal disruption, and restoration of the blood brain barrier. In animals, P188 has been shown to improve sensorimotor functions, as well as spatial learning and memory., Competing Interests: I do not have any declarations of interest., (© 2024 The Authors.)

Ruthenium(II) trisdiimine complexes of the formula, [Ru(dip) n (L-L) 3-n ] 2+ , where n=0-3; dip=4,7-diphenyl-1,10-phenanthroline; L-L=2,2'-bipyridine (bpy) or 1,10-phenanthroline (phen) were prepared and tested for cytotoxicity in two cell lines (H358, MCF7). Cellular uptake and subcellular localization were determined by harvesting treated cells and determining the ruthenium concentration in whole or fractionated cells (cytosolic, nuclear, mitochondrial/ ER/Golgi, and cytoskeletal proteins) by Ru ICP-MS. The logP values for the chloride salts of these complexes were measured and the data were analyzed to determine the role of lipophilicity versus structure in the various biological assays. Cellular uptake increased with lipophilicity but shows the biggest jump when the complex contains two or more dip ligands. Significantly, preferential cytoskeletal localization is also correlated with increased cytotoxicity. All of the RPCs promote tubulin polymerization in vitro, but [Ru(dip) 2 phen] 2+ and [Ru(dip) 3 ] 2+ show the strongest activity. Analysis of the pellet formed by centrifugation of MTs formed in the presence of [Ru(dip) 2 phen] 2+ establish a binding stoichiometry of one RPC per tubulin heterodimer. Complexes of the general formula [Ru(dip) 2 (L-L)] 2+ possess the necessary characteristics to target the cytoskeleton in live cells and increase cytotoxicity, however the nature of the L-L ligand does influence the extent of the effect., (© 2023 Wiley-VCH GmbH.)

Sub/supercritical fluid chromatography (SFC) is a green separation technique that has been used to separate a wide variety of compounds and is proven to be immensely useful for chiral separations. However, SFC is currently not thought to be applicable for ionic compounds due to their low solubility in CO 2 , even with additives and organic modifiers. Recently, a large amount of research has been centered on octahedral complexes of Ru(II) and Os(II) with bidentate polypyridyl ligands due to their ability to serve in cancer treatment and other biological activities. These compounds exist as the delta (Δ) and lambda (Λ) enantiomers. Previously, similar compounds have been enantiomerically separated using HPLC and capillary electrophoresis, but never with SFC. Cyclofructan-6 (CF6) derivatized with (R)-naphthyl ethyl (RN) groups has been proven to be an effective chiral stationary phase for these separations in HPLC. This column chemistry was expanded to SFC to provide the first chiral separation of a wide variety (23 complexes in total) of ionic octahedral polypyridyl complexes. Unexpected behavior for mixing methanol and acetonitrile as the organic modifier will be discussed, along with the effects of additives. Enantioselectivity on CF6-RN chemistry is shown to be dependent on the conjugation level and rigidity of the metal complexes. Mass transfer kinetic behavior is also shown, and high-efficiency baseline resolved rapid separations are shown for fast screening or quantitation of representative coordination complexes., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: S.A.M. has a potential research conflict of interest due to a financial interest with Theralase Technologies, Inc. and PhotoDynamic, Inc. A management plan has been created to preserve objectivity in research in accordance with UTA policy., (Copyright © 2022 Elsevier B.V. All rights reserved.)